Bloomberg -- Basilea Pharmaceutica AG rose the most in 11 months in Zurich trading after Helvea SA said the company’s low valuation, cash reserves and portfolio of anti- infectives make it an “imminent” takeover target.
Bloomberg -- Basilea Pharmaceutica AG rose the most in 11 months in Zurich trading after Helvea SA said the company’s low valuation, cash reserves and portfolio of anti- infectives make it an “imminent” takeover target.